Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Atrial Fibrillation in Hypertrophic Cardiomyopathy
Patients with hypertrophic cardiomyopathy are much more likely to develop atrial fibrillation than the general public. Patients with atrial fibrillation may develop symptoms of shortness of breath, dizziness, chest pain, and racing heart. The diagnosis is made with electrocardiogram (ECG) or ECG monitoring. Patients will frequently need to be on medications to slow the heart rate or restore normal rhythm.
In studies of patients with hypertrophic cardiomyopathy with stroke, nearly 90% of patients had atrial fibrillation. The risk of stroke appears to be less in patients with atrial fibrillation and hypertrophic cardiomyopathy having warfarin (Coumadin) anticoagulation.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.